Gyros signs three distributor agreements with Alpha Analytical, Spinco Biotech and HVD Vertriebs
Agreements will enable Gyros to reach growing biopharmaceutical markets
Gyros AB, a leader in the automation of miniaturized immunoassays, announced today that it has signed agreements with Alpha Analytical PTE Ltd (Alpha), Spinco Biotech Pvt Ltd (Spinco) and HVD Vertriebs Ges.m.b.H (HVD) to become sole distributors of the company’s immunoassay platform for the biopharmaceutical industry in their respective markets.
Erik Walldén, CEO at Gyros, commented on the company’s selection: “Alpha is a well established provider of analytical tools to the growing biopharmaceutical industry in Singapore. Both Spinco, a distributor with broad coverage of the Indian market, and HVD, well-known throughout the Middle East, Russia and Africa, have an excellent reputation for customer service. Such factors featured significantly in our choice.”
Mr. Walldén continued: “Following a successful year in which we increased our presence significantly in North America and Europe and established distributorships in Japan and Korea, we believe the time is right to continue to expand our global coverage. We look forward to a fruitful relationship with our new partners.”
Major biopharmaceutical companies and their service providers currently utilize the Gyros immunoassay platform to boost time-critical workflows and meet increasing regulatory demands in the development of biotherapeutics and vaccines. By reducing turnaround times and enabling scientists to make data-driven decisions based on high quality data, the Gyros platform increases overall productivity and efficiency. Advantages such as unattended running of samples and assay development, within days rather than months, ensure substantial time-saving for analysts. Working at nanoliter scale cuts sample consumption and significantly reduces the cost of preclinical studies. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
Gyros is headquartered in Uppsala, Sweden with regional sales and support offices in the USA and Europe and a growing distributor network.
For Gyros AB
Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: firstname.lastname@example.org / email@example.com
Notes to editors:
About Gyros (www.gyros.com)
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.